Global Information
회사소개 | 문의 | 비교리스트

세계의 헌터증후군 치료 시장(2019-2025년)

Hunter Syndrome Treatment Market 2019-2025

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949548
페이지 정보 영문
가격
US $ 3,600 ₩ 4,023,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,364,000 Printable PDF (Enterprise License)


세계의 헌터증후군 치료 시장(2019-2025년) Hunter Syndrome Treatment Market 2019-2025
발행일 : 2020년 06월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

헌터증후군은 효소의 기능 부전에 의해 발생하는 매우 희귀한 유전성 질환이며, 주로 남자아이에게서 보입니다. National MPS Society에 따르면 헌터증후군이 발병하는 것은 10만-17만 명당 1명이라고 합니다. 헌터증후군의 치료법으로는 효소 보충 요법(ERT), 조혈모세포 이식(HSCT), 유전자 치료, 골수 이식, 편도적출 술 등이 있습니다.

세계의 헌터증후군 치료 시장을 조사했으며, 시장의 개요, 경쟁 구도, 시장의 방향성을 결정하는 요인, 치료법별, 지역별 분석, 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 리포트 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트의 인사이트와 시장의 최신 동향

제3장 경쟁 구도

  • 각사의 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • Takeda Pharmaceutical Company
    • Clinigen Group PLC
    • JCR Pharmaceuticals Co Ltd.
    • RegenxBio Inc.
    • ArmaGen, Inc.

제4장 시장 결정요인

  • 성장 촉진요인
  • 성장 저해요인
  • 시장 기회

제5장 시장 세분화

  • 치료법별 시장
    • 효소 보충 요법(ERT)
    • 조혈모세포 이식(HSCT)
    • 기타(유전자 치료, 골수 이식, 편도적출술)

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타
  • 기타 지역

제7장 기업 개요

  • ArmaGen, Inc.
  • Bioasis Technologies, Inc.
  • Clinigen Group PLC
  • Denali Therapeutics, Inc.
  • EstevePharmaceuticals, S.A.
  • GC Pharma Corp.
  • Inventiva S.A.
  • JCR Pharmaceuticals Co., Ltd.
  • REGENXBIO, Inc.
  • Sangamo Therapeutics, Inc.
  • Shire Plc.(Takeda Pharmaceutical Company)
KSA 20.07.31

LIST OF TABLES

  • 1. GLOBAL HUNTER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)

2. GLOBAL ENZYME REPLACEMENT THERAPY (ERT) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)

3. GLOBAL HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)

4. GLOBALOTHERS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)

  • 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 6. NORTH AMERICAN HUNTER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 7. NORTH AMERICAN HUNTER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 8. EUROPEAN HUNTER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 9. EUROPEAN HUNTER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 10. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 11. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 12. REST OF THE WORLDGLOBAL HUNTER SYNDROME TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HUNTER SYNDROME TREATMENT MARKET SHARE BY TREATMENT, 2018 VS 2025 (%)
  • 2. GLOBAL HUNTER SYNDROME TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 3. US HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 4. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. UK HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ROE HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. INDIA HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF THE WORLD HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)

Global Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report, by Treatment (Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), Others) and Forecast Period 2019-2025

The global hunter syndrome treatment market is estimated to grow at a moderate CAGR during the forecast period. Hunter syndrome is a very rare genetic disorder caused by the malfunction of the enzyme, it happens due to the deficiency of the enzyme. Hunter syndrome is mainly seen in boys. According to the National MPS Society, 1 in 1,00,000 to 1 in 1,70,000 every male are affected by the hunter syndrome.

Innovative novel therapies in clinical trials and increasing R&D activities by major market players for the development of hunter syndrome treatment are the major two driving factors that are propelling the global hunter syndrome treatment market. For instance, in August 2018, ArmaGen received the US Orphan Drug Designation for AGT-184. It is an investigational enzyme replacement therapy (ERT) for the treatment of hunter syndrome treatment.

The global hunter syndrome treatment market is segmented based on treatment into Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), and others (Gene Therapy, Bone Marrow Transplant, and Tonsillectomy). Based on geography, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and RoW.

The major players providing drugs of hunter syndrome treatment includeShire Plc. (Takeda Pharmaceutical Company), GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., ArmaGen Inc., Inventiva S.A., Denali Therapeutics Inc., and others.The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale.

Few Recent Developments in the Market-

  • In November 2019, Bioasis announced the allowance of patent applications of xB3 platform in Japan, later in 2020, it allowed patent applications in the US and Europe.
  • In June 2019, Denali Therapeutics got approval from the US FDA for DNL310, it is an enzyme replacement therapy for patients withHunter syndrome.

Research Methodology

The market study of the global hunter syndrome treatmentmarket is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Reports of companies involved in the market
  • Authentic Public Databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog

The Report Covers:

  • Comprehensive research methodology of the global hunter syndrome treatmentmarket.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global hunter syndrome treatmentmarket.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusions

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Takeda Pharmaceutical Company
      • 3.3.1.1. Overview
      • 3.3.1.2. SWOT Analysis
      • 3.3.1.3. Recent Developments
    • 3.3.2. Clinigen Group PLC
      • 3.3.2.1. Overview
      • 3.3.2.2. SWOT Analysis
      • 3.3.2.3. Recent Developments
    • 3.3.3. JCR Pharmaceuticals Co Ltd.
      • 3.3.3.1. Overview
      • 3.3.3.2. SWOT Analysis
      • 3.3.3.3. Recent Developments
    • 3.3.4. RegenxBio Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. SWOT Analysis
      • 3.3.4.3. Recent Developments
    • 3.3.5. ArmaGen, Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. SWOT Analysis
      • 3.3.5.3. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Hunter Syndrome Treatment Market byTreatment
    • 5.1.1. Enzyme Replacement Therapy (ERT)
    • 5.1.2. Hematopoietic Stem Cell Transplant (HSCT)
    • 5.1.3. Others ( Gene Therapy, Bone Marrow Transplant, Tonsillectomy)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. ArmaGen, Inc.
  • 7.2. Bioasis Technologies, Inc.
  • 7.3. Clinigen Group PLC
  • 7.4. Denali Therapeutics, Inc.
  • 7.5. EstevePharmaceuticals, S.A.
  • 7.6. GC Pharma Corp.
  • 7.7. Inventiva S.A.
  • 7.8. JCR Pharmaceuticals Co., Ltd.
  • 7.9. REGENXBIO, Inc.
  • 7.10. Sangamo Therapeutics, Inc.
  • 7.11. Shire Plc. (Takeda Pharmaceutical Company)
Back to Top
전화 문의
F A Q